EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access

Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma

Alexandra Jackovich, Barbara J Gitlitz, Justin Wayne Wong Tiu-Lim, Vinay Duddalwar, Kevin George King, Anthony B El-Khoueiry, Jacob Stephen Thomas, Denice Tsao-Wei, David I Quinn, Parkash S Gill, Jorge J Nieva

Oncotarget · 2024

DOI: 10.18632/oncotarget.28605 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Oncotarget, 2024. Verfasst von Alexandra Jackovich und 10 weiteren Autor:innen. Beteiligte Einrichtung: Rutgers New Jersey Medical School, Newark, NJ 07103, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Head and Neck Neoplasms, Ephrin-B2, Squamous Cell Carcinoma of Head and Neck. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedHead and Neck NeoplasmsEphrin-B2Squamous Cell Carcinoma of Head and NeckReceptor, EphB4HumansFemaleMaleMiddle AgedAgedAdultCarcinoma, Squamous CellAntineoplastic Combined Chemotherapy ProtocolsPapillomavirus InfectionsTreatment OutcomeRecombinant Fusion ProteinsAged, 80 and over

Stichwörter der Autor:innen

EphB4EphrinB2HNSCCHPV-negativepembrolizumab

Substanzen

Antibodies, Monoclonal, HumanizedpembrolizumabEphrin-B2Receptor, EphB4EPHB4 protein, humanRecombinant Fusion ProteinsEFNB2 protein, human

Autor:innen und Institutionen

  • Rutgers New Jersey Medical School, Newark, NJ 07103, USA.
  • Division of Medical Oncology, University of Southern California, Los Angeles, CA 90007, USA.

Förderung

  • NCI NIH HHS

Zitieren

APA

Jackovich, A., Gitlitz, B. J., Tiu-Lim, J. W. W., Duddalwar, V., King, K. G., El-Khoueiry, A. B., Thomas, J. S., Tsao-Wei, D., Quinn, D. I., Gill, P. S., & Nieva, J. J. (2024). Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma. Oncotarget. https://doi.org/10.18632/oncotarget.28605

Vancouver

Jackovich A, Gitlitz BJ, Tiu-Lim JWW, Duddalwar V, King KG, El-Khoueiry AB, et al. Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma. Oncotarget. 2024. doi:10.18632/oncotarget.28605

BibTeX
@article{Jackovich2024,
  author = {Jackovich, Alexandra and Gitlitz, Barbara J and Tiu-Lim, Justin Wayne Wong and Duddalwar, Vinay and King, Kevin George and El-Khoueiry, Anthony B and Thomas, Jacob Stephen and Tsao-Wei, Denice and Quinn, David I and Gill, Parkash S and Nieva, Jorge J},
  title = {Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma},
  journal = {Oncotarget},
  year = {2024},
  doi = {10.18632/oncotarget.28605}
}
Kostenlos starten →